UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Reuters
UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch (Adds details on pricing, comment from company, background) By Dania Nadeem April 27 (Reuters) - Neurocrine Biosciences Inc’s said on Monday its add-on treatment for patients with Parkinson’s disease had received U.S. approval, but would delay launch until later this year due to disruptions caused by the COVID-19 pandemic. As the virus outbreak prompts social distancing and forces hospitals to cancel unnecessary visits, including that from drug sales personnel, operations of pharmaceutical companies are getting disrupted, including launches. “This is not an appropriate time to launch the drug into the neurology community,” Neurocrine Chief Executive Officer Kevin Gorman told Reuters ahead of the announcement of the drug’s approval by the U.S. Food and Drug Administration. A month’s supply of the drug, Ongentys, would have a list price below $670, around the range of other similar drugs in the market
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab) [Yahoo! Finance]Yahoo! Finance
- Active Pharmaceutical Ingredient Market Trends Signal Growth Towards USD 446.6 Billion by 2032 With CAGR AT 6.4% [Yahoo! Finance]Yahoo! Finance
- Here's Why Merck & Co. (MRK) Outperformed in Q1 [Yahoo! Finance]Yahoo! Finance
- TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer [Yahoo! Finance]Yahoo! Finance
- How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- MRK's page on the SEC website